Quantitative Investment Management LLC Takes $529,000 Position in Ascendis Pharma A/S $ASND

Quantitative Investment Management LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 1,985 shares of the biotechnology company’s stock, valued at approximately $529,000.

Other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP lifted its stake in Ascendis Pharma A/S by 95.9% during the third quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock worth $357,645,000 after purchasing an additional 880,836 shares during the period. Perceptive Advisors LLC grew its stake in shares of Ascendis Pharma A/S by 41.6% in the 1st quarter. Perceptive Advisors LLC now owns 1,531,421 shares of the biotechnology company’s stock valued at $350,282,000 after purchasing an additional 450,000 shares during the period. Principal Financial Group Inc. grew its stake in shares of Ascendis Pharma A/S by 29.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company’s stock valued at $218,871,000 after purchasing an additional 232,730 shares during the period. Vestal Point Capital LP raised its holdings in shares of Ascendis Pharma A/S by 200.0% in the 3rd quarter. Vestal Point Capital LP now owns 600,000 shares of the biotechnology company’s stock worth $119,286,000 after buying an additional 400,000 shares in the last quarter. Finally, FIL Ltd lifted its position in shares of Ascendis Pharma A/S by 4.2% during the 4th quarter. FIL Ltd now owns 478,641 shares of the biotechnology company’s stock worth $102,065,000 after buying an additional 19,301 shares during the period.

Insider Activity

In other Ascendis Pharma A/S news, Director Jean Jacques Bienaime purchased 2,000 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was acquired at an average cost of $246.33 per share, with a total value of $492,660.00. Following the completion of the acquisition, the director directly owned 2,900 shares of the company’s stock, valued at $714,357. This represents a 222.22% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 40.00% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ASND has been the topic of a number of analyst reports. Bank of America lowered their price target on Ascendis Pharma A/S from $306.00 to $304.00 and set a “buy” rating on the stock in a research report on Monday. Citigroup started coverage on Ascendis Pharma A/S in a report on Monday, May 18th. They set a “buy” rating and a $355.00 price objective for the company. Morgan Stanley reduced their target price on shares of Ascendis Pharma A/S from $275.00 to $273.00 and set an “overweight” rating on the stock in a research note on Tuesday. Wells Fargo & Company lowered their target price on shares of Ascendis Pharma A/S from $330.00 to $326.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. Finally, Oppenheimer reiterated an “outperform” rating and set a $312.00 target price on shares of Ascendis Pharma A/S in a research report on Tuesday. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $310.05.

Ascendis Pharma A/S Stock Down 1.1%

NASDAQ ASND opened at $260.25 on Wednesday. The firm has a market cap of $16.23 billion, a PE ratio of 20.19 and a beta of 0.35. Ascendis Pharma A/S has a one year low of $186.05 and a one year high of $282.15. The stock’s 50 day simple moving average is $256.87 and its 200 day simple moving average is $239.75. The company has a debt-to-equity ratio of 0.27, a current ratio of 2.99 and a quick ratio of 2.32.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings results on Friday, August 14th. The biotechnology company reported $1.03 earnings per share for the quarter, missing analysts’ consensus estimates of $1.71 by ($0.68). The business had revenue of $387.22 million for the quarter, compared to analyst estimates of $376.75 million. Ascendis Pharma A/S had a net margin of 70.99% and a return on equity of 32.54%. As a group, sell-side analysts forecast that Ascendis Pharma A/S will post 3.9 earnings per share for the current fiscal year.

Ascendis Pharma A/S News Summary

Here are the key news stories impacting Ascendis Pharma A/S this week:

• Positive Sentiment: BioMarin settlement removes litigation overhang: Ascendis and BioMarin entered a binding term sheet for a global settlement and license agreement covering YUVIWEL® and navepegritide-related products. The agreement is intended to resolve all litigation and disputes between the companies, reducing legal uncertainty around the product. Ascendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL Shares increased following news of the license deal. Ascendis Pharma Shares Rise 6% Over License Deal With BioMarin Pharmaceutical
• Positive Sentiment: Wedbush remains bullish: Wedbush reaffirmed its “Outperform” rating and set a $327 price target, implying substantial upside from the referenced share price. The rating signals continued confidence in Ascendis’ growth prospects and product pipeline. Wedbush Reaffirms Ascendis Pharma Outperform Rating
• Neutral Sentiment: Analyst consensus remains favorable: Ascendis Pharma received an average analyst rating of “Buy,” indicating that Wall Street sentiment remains broadly positive despite recent estimate revisions. Ascendis Pharma Receives Average Rating of Buy from Analysts
• Negative Sentiment: HC Wainwright cuts forward EPS forecasts: The firm reduced its estimates for the third and fourth quarters of 2026, all four quarters of 2027, and FY2027 EPS to $11.25 from $11.88. Although HC Wainwright maintained its “Buy” rating and $345 price target, the lower forecasts suggest a more cautious outlook for near-term earnings growth.
• Negative Sentiment: Bank of America trims its target: Bank of America lowered its price objective to $304 from $306 while retaining a “Buy” rating, representing a modest reduction in expected upside.

About Ascendis Pharma A/S

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.